Professor, Dept of Oncology-Pathology, Karolinska Institutet, 2006-
Professor II, CCBIO, Bergen University, 2016-
Associate Professor, Uppsala University, 1995
Post-doc, Cold Spring Harbor Laboratory, 1992-93
Ph.D., Uppsala University, 1990
Our research group performs translation studies on autocrine and paracrine growth factor signaling in the tumor microenvironment, with particular emphasis on regulation of cancer-associated fibroblasts.
Author of more than 140 original research articles and 45 reviews (Nat Rev Can, Cancer Cell, Trends in cell Biology and Trends in Cancer); h-factor 55.
Completed supervision of 13 PhD students and 15+ post-doctoral fellows of which the majority continues academic research. Four of these are full professors and 7 have been promoted to PI or junior PI positions.
Coordinator STARGET – a Linnaeus center for translational studies on the tumor microenvironment with funding from VR 2006-16.
Co-director StratCan – the strategic research program in cancer at Karolinska Institutet, 2010-18
Ad-hoc reviewer for the Nobel Assembly and the Royal Academy of Science (Sjöberg Prize).
Member of the Editorial Board Cancer Research (2015-).
Supported last years by research grants from Swedish Cancer Society, Swedish Research Council, “Kreftforeningen”, Stockholm City Council (ALF), “Radiumhemmets forskningsfonder”, KAW (E Arner PI), Eli-Lilly and Roche.
External grant reviewer for Cancerfonden, Barncancerfonden, SSMF, ERC and national European agencies including CRUK and Wellcome Trust. Reviewer for e.g. Nature, Nature Medicine, Nature Comm., Nat Rev Cancer, Nat Rev Clin Onc, Cancer Cell, EMBO J.
Main- or co-organizer of UICC Advanced Course of Cell Signaling and Cancer, 1999; Nobel Conference on Breast Cancer, 2012 and Swedish Cancer Research Meeting 2014.
Ad hoc member of international scientific advisory boards for e.g. ImClone, Eli-Lilly and Novartis.
10 selected publications
Microvascular mural cells in cancer, Ostman A, Corvigno S, Trends in Cancer (in press)
Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties.
Cancer Res. 2014 Jun;74(11):2999-3010
STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer.
Cancer Res. 2013 Feb;73(4):1287-97
The tumor microenvironment controls drug sensitivity.
Nat. Med. 2012 Sep;18(9):1332-4
Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer.
Cancer Res. 2010 Apr;70(7):2644-54
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.
Proc. Natl. Acad. Sci. U.S.A. 2009 Mar;106(9):3414-9
High interstitial fluid pressure - an obstacle in cancer therapy.
Nat. Rev. Cancer 2004 Oct;4(10):806-13
PDGF receptors as cancer drug targets.
Cancer Cell 2003 May;3(5):439-43
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Cancer Res. 2002 Oct;62(19):5476-84
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.
Nat. Cell Biol. 2000 May;2(5):302-9